Verona Pharma Share Discussion Threads

[fatgreek] 08/12/2015 08:40

Looking good to get back to the 4p mark short term...

[fatgreek] 06/12/2015 16:15

Verona Pharma Plc (LON:VRP) insider Ebsworth,David purchased 370,000 shares of Verona Pharma Plc stock in a transaction dated Thursday, December 3rd. The stock was acquired at an average cost of GBX 3 ($0.05) per share, with a total value of £11,100 ($16,699.26).Shares of Verona Pharma Plc (LON:VRP) traded up 2.40% during midday trading on Thursday, hitting GBX 3.20. The stock had a trading volume of 1,459,249 shares. Verona Pharma Plc has a 12-month low of GBX 1.15 and a 12-month high of GBX 6.95. The company's 50-day moving average price is GBX 3.29 and its 200-day moving average price is GBX 4.36. The firm's market cap is GBX 32.32 million.Separately, N+1 Singer reaffirmed a "corporate" rating on shares of Verona Pharma Plc in a research report on Wednesday, November 11th.Verona Pharma plc is the United Kingdom-based biotechnology company. The principal activity of the company is the development of novel, first-in-class drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (LON:VRP), asthma and cough. The Company's operating segments include clinical and basic research. The Company operates in two geographical segments: the United Kingdom and Canada. The Company's product pipeline focuses on research, discovery and development of new therapeutic drugs for the treatment of chronic respiratory diseases. At present there are three products: RPL554, VRP700 and NAIPs. RPL554 and VRP700 are in the clinical phase, RPL554 having successfully completed Phase 1 and 2 trials, VRP700 having successfully completed a Phase 2 trial, and NAIPs are in the basic research phase. The Company currently has one wholly owned subsidiary, Rhinopharma Limited.

[corbine] 04/12/2015 09:55

bang bang- pass on your question lol, further, when i go to like a post its already done them to lots without me even trying? w.tf? :-)

[fatgreek] 04/12/2015 08:51

Definitely putting his money where his mouth is.

[oldvic] 04/12/2015 08:20

this is looking good
director buy tells a true story

[bangbang1] 03/12/2015 17:53

how do you see who tick your post down ?

any problems, answer me directly

[fatgreek] 03/12/2015 16:33

Always good when a director buys...

[bangbang1] 03/12/2015 16:24

Good stuff. So no placing then.

[aimshares] 03/12/2015 16:05

Rns director buyhttp://www.investegate.co.uk/verona-pharma-plc--vrp-/prn/director-dealing/20151203160220PE993/

[corbine] 01/12/2015 17:14

after hours rns guys..
:_)

[timbo003] 01/12/2015 15:33

>>>>Vas, agree with your comments, I don't get that sales strategy either.

I had intended to post the link below (similar subject matter, same author, same journal, dated November 30th 2015) but ended up posting the older article by mistake.

[vasilis] 01/12/2015 14:39

Tim,

The sales strategy outlined in that article July 2014 for Anoro and Breo appears not to have improved as this article from this October comments upon, and in addition, Avodart (dutasteride) for benign prostatic hyperplasia is also coming under commercial attack -

To be honest, I don't understand the sales strategy logic behind Anoro and Breo (Avodart's emerging markets strategy makes much more sense), and if the BOD has any sense they will listen to what the reps on the street are saying regarding Anoro/Breo rather than keep sticking to some weird sales 'incentive' plan dreamt up by I not who and clearly not working as well as expected from the viewpoint of some external commentators. If it's also true that good sales people are so disenchanted with the strategy that they are walking and going to the competition then that's surely a double whammy for GSK.

All in all, even more reason of course for GSK to now keep a very beady eye on RPL554 since if GSK ignores RPL554 and it jumps through all the hoops and is partnered elsewhere, the potential commercial damage to GSK for medicines in this area can only increase from what I can see.

[fatgreek] 01/12/2015 14:13

You saying GSK are sniffing us?

[bangbang1] 01/12/2015 13:40

Since when bladeboy ?

[bladeboy1] 01/12/2015 13:28

Timbo003,GSK ARE ON IT!!!

[timbo003] 01/12/2015 11:55

Some interesting commentary on why GSK's Breo and Anoro are off to such a lack lustre start



I suspect the real problem is that there is a generally held perception that Breo and Anoro are just longer acting versions of what is already out there.

Advair is a hard act to follow, if only GSK had an alternative fast acting, long duration bronchodilator/anti-inflanmmatory with a unique mechanism of action instead, which also just happened to have an additive and/or syngergistic effect with current therapies.

I wonder where they should be looking?

[corbine] 28/11/2015 10:40

id like vrp to address this question in any q and a they do or if anyone gets any dialogue with vrp ask them the above for me?
thanks

ps vrp- i know you read this board so address it when u can please-ta

[corbine] 28/11/2015 10:38

thanks timbo-thats the one and clearly i havent missed the latest they just with held it for some reason-even current is mighty impressive imo timbo-any thoughts on my earlier post using 554 even when er exacerbation when patients either already on 02 or given 02 due to reason of admission sats crash etc and normally given 15 litres high flo 02 to help sats the 554 would of course help tackle the exacerbation in other ways/assist the 02 therapy as a multi pronged attack at stabiliszing /helping patient?
anyone with thoughts in this field?
corbs :-)

[timbo003] 28/11/2015 08:16

>>>corbs

I think this is the most recent FEV vs time chart we have (see below) and it's the one they keep rolling out at all the presentations, including the recent presentation on November 3rd 3015 (note at bottom of slide states that it is from the 2013 Lancet publication).

As we know there have been further study results announced since then (on the new improved formula with a higher dose), which sound as if they are going to be as impressive (if not more impressive) when presented as mean FEV vs time profiles:

March 2015: ...
June 2015: ....
Sept 2015: ....

The company have chosen not to make these publically available yet. Maybe they will appear at one or more of the next major respiratory conferences next spring which could the most appropriate time to make a splash.

[corbine] 27/11/2015 14:01

can people also remind me if any of the earlier current tests have been done on patients living with 02 24/7 or not as i suspect during emergency admissions (exascerbations) for copders, not only will mod/severe copders (emphysema/asthmatics, bronchitis etc) those with the disease will also be cases on oxygen 24/7 or 18 hours daily (LTOT).
i suspect if tested they would also see immediate benefits when admitted to er during such exacerbation attacks, even when docs go to 15 litres high flo 02 initially when exacerbation happens and sats (02) are low. adding 5554 whilst on 02 will also show immediate fev1 benefits which COULD help patients at immediate risk (and some go straight to resuss depending on how bad the exacerbation is even if they are normally only mod/severe and not even 02 users at that stage of disease.
the thought of immediate benefits in such live time life/death theaters of medical support could be massive in help said patients.
in my view.
currently they use nebulised ventolin (salbutomol-with added ipraptroprium bromide - to help the patient.
vrp have already said they can at least match and beat ventolin/slabutomol which is actually a patients rescue drug for copd and also asthma during an attack/ exacerbation. its also adminsitered orally as an inhaler during normal day to day useage, as well as nebulised format for those that struggle with poor fev1 (1 sec blow outs)which often happens to those that dialy use just inhalers, often find during er emergency admissions the nebs are used as they are far more effective and potent during an attack where the airway fev1 may be compromised further, )even if temporary), the docs wont take chances and hit you with nebbed solutions that get deeper into the airways where the help is needed more immediately to assist said patients..
apols for ramble, just giving a point of view as patient from many er admissions i n such cases so just relaying how i see where vrp 554 can benefit above and trump other drugs in current nhs armoury.
as long as recent results continue from here on or even better themselves in other areas (asthma cf etc)
best wishes corbs.
:-)
imo jmo gl dyoR etc

[corbine] 27/11/2015 13:46

i suspect if any of the current or future trials show fev1 to improve above 15% for a long duration, it will interest the major tier ones if we havent already (they are and have been in discussions with some potential partners) although im unsure in which formats.
as its friday id like to see a link here on the lineage showing the recent result with the graph showing the fev1 and duration as this is dynamite in my view.
(ask a respiratory consultant if he likes that graph and hell smile at you is my view)
impressive-thus far.
im unable to dig for the graph link due to medded out so id appreciate the link to make me smile again today folks :-)

[bangbang1] 27/11/2015 13:10

4th day in a row where you can't get a quote to buy above £5 k

[corbine] 26/11/2015 10:08

its a free bb greek but for past few years has been a good one showing research and links to such and not packed with daily talk of share price other than when rns related news arrives. feel free to post your intel/research. i think point being made was no need to talk multiple times a day about share price which turns us into a lse type board with nothing worth reading. for years this has been an informed board with a few brilliant posters who understand the company fully and share some excellent links many would have trouble finding.
have a good day all.
corbs:-0)

[shakin not stirred] 26/11/2015 00:50

fat geek. yes looking good ,but we have seen this all before so you may wish to temper your enthusiasm as may prove to be misplaced. Time will tell